Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kairos Pharma will share a corporate overview and offer investor one-on-one meetings at the H.C. Wainwright conference, with webcast access online.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES--(BUSINESS WIRE)-- Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28^th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

Presentation Date: September 14, 2026

Time: 4:00 PM Eastern Time (Holmes 1)

Webcast Link: Available Here

A webcast of the presentation can be accessed on the investor relations section of the Kairos Pharma website. A replay of the webcast will be archived and available following the event for 90 days.

Dr. Yu will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:

https://hcwevents.com/annualconference/

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. For more information, visit kairospharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909429715/en/

CORE IR
investors@kairospharma.com
https://investors.kairospharma.com/overview/default.aspx

Source: Kairos Pharma, Ltd

Key Terms

cd105 medical

A protein found on the surface of certain cells, especially those that line and form blood vessels, known as endoglin. It acts as a marker of new or active blood-vessel growth and is used in research, diagnostic tests, and as a potential drug target in areas like cancer and cardiovascular disease. Investors track CD105 because clinical trial results, diagnostic adoption, or regulatory actions involving it can influence the value of companies developing related tests or therapies.

structural biology technical

Study of the three-dimensional shapes and physical arrangements of biological molecules—mainly proteins, nucleic acids, and their complexes—and how those shapes determine their function and interactions. Think of it as mapping the parts and fit of tiny machines inside cells so scientists understand how they work or how a drug might block or change them. Investors watch structural biology because those molecular blueprints guide drug design, patent claims, and the scientific value behind biotech products.